Loading patent…
AssigneeBoyce Thompson Institute
InventorsDwayne Kirk, Hugh Mason, Amanda Walmsley, Charles Arntzen
Estimating the term…
The present invention provides for processing methods that preserve pharmaceutical proteins expressed in plants. Herein raw plant tissue is reduced to a stable homogenate without significant loss of protein or pharmaceutical potency. The homogenate can be used directly for pharmaceutical purposes without the need to further extract, purify, or precipitate the pharmaceutical protein. The present invention further provides a method of effective immunocontraception for animal and human application. Methods are disclosed for producing transgenic plants or plant cells which express contraceptive proteins, and which can be delivered whole, in part, or after processing, to an animal to cause a contraceptive effect in the target species.
A method for producing a stable dry homogenate of a transgenic plant expressing a heterologous protein comprising:
A stable dry homogenate comprising a dehydrated transgenic plant material containing a transgenic protein.
A method of contraception comprising:
A method of contraception comprising:
A method of contraception comprising:
A method of contraception comprising:
A method of inducing a mucosal immune response comprising:
A transgenic plant comprising transgenic plant material which expresses a nucleic acid sequence encoding a contraceptive polypeptide, wherein administering said transgenic plant material to an animal induces a mucosal immune response in said animal to said contraceptive protein, and wherein said administering reduces the average number of offspring produced per breeding cycle by said animal by at least 50%.
A transgenic plant comprising transgenic plant material which expresses a nucleic acid sequence encoding a contraceptive polypeptide, wherein said nucleic acid sequence encoding a contraceptive polypeptide is not expressed on a viral particle, and wherein administration of said transgenic plant material to an animal induces a mucosal immune response in said animal to said contraceptive protein.
A transgenic plant comprising transgenic plant material which express a nucleic acid sequence encoding a contraceptive polypeptide, and wherein said administration reduces the average number of offspring per breeding cycle produced by said animal to which said transgenic plant material is administered by at least 50%.
An edible transgenic plant comprising transgenic plant material which express a nucleic acid sequence encoding a contraceptive polypeptide, wherein administration of said transgenic plant material to an animal induces a mucosal immune response in said animal to said contraceptive protein, and wherein said nucleic acid is integrated into a plant chromosome.
A plant cell comprising a nucleic acid vector, wherein said nucleic acid vector encodes a contraceptive polypeptide, wherein said nucleic acid vector is incorporated into and expressed from the chromosome of said plant cell, and wherein administration of said plant cell to an animal reduces the average number of offspring produced per breeding cycle by said animal by at least 50%.
A plasmid vector for transforming a plant cell comprising:
A composition comprising a saponin adjuvant in admixture with processed transgenic plant material for oral administration to an animal, wherein said administration reduces the number of offspring produced by said animal per breeding cycle by at least 50%.
Dependencies are inferred from the claim text.